Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Change in Cash (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Change in Cash for 12 consecutive years, with $473074.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 403.58% year-over-year to $473074.0, compared with a TTM value of $463170.0 through Dec 2025, up 215.01%, and an annual FY2025 reading of $463170.0, up 215.01% over the prior year.
  • Change in Cash was $473074.0 for Q4 2025 at Abvc Biopharma, up from -$222415.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $2.8 million in Q3 2021 and bottomed at -$3.1 million in Q1 2022.
  • Average Change in Cash over 5 years is -$183719.3, with a median of -$15337.0 recorded in 2024.
  • Peak annual rise in Change in Cash hit 1197.29% in 2021, while the deepest fall reached 7978.14% in 2021.
  • Year by year, Change in Cash stood at $2.1 million in 2021, then plummeted by 127.34% to -$578419.0 in 2022, then soared by 30.13% to -$404157.0 in 2023, then skyrocketed by 123.24% to $93942.0 in 2024, then surged by 403.58% to $473074.0 in 2025.
  • Business Quant data shows Change in Cash for ABVC at $473074.0 in Q4 2025, -$222415.0 in Q3 2025, and $316758.0 in Q2 2025.